Abbasi Ezatolah, Ghazavi Ahad, Hassanvand Amouzadeh Masoud, Valizadeh Mohammad, Matinkhah Masoud
Pediatric Neurology, Urmia University of Medical Sciences, Urmia, Iran.
Neuroscience Research Center, Qom University of Medical Sciences,Qom,Iran.
Iran J Child Neurol. 2020 Fall;14(4):43-53.
A breath-holdingspell (BHS) is defined as an apnea attack following an initial stressful event like anger, sadness, and fear, a painful event like falling or head trauma or any stressful psychology event. This study was designed to assessthe comparative efficacy of levetiracetam plus iron and iron alone in reducingthe BHS frequency in children aged 6 months to 5 years.
MATERIALS &METHOD: This study was designed asa double-blinded randomized clinical trial. Sixty patients aged 6 months to 5 years were assigned into two groups, withthe first group (A) receiving onlyiron and the second group (B)receiving levetiracetam plus iron. At the end of the study, the efficacy of therapywas analyzed comparatively in these groups.
In this study, the mean number of attacks was 3.94 ± 2.69 before treatment and 1.71 ± 1.99after treatmentin the group A,while it was 6.39 ± 5.7 before treatment and 0.37 ± 1.03after treatment in the group B.The mean number of attacksafter treatment was lower in group B than in group A. In fact, there was a significant difference between the two groups in terms of the number of attacks after treatment (P = 0.003).
Levetiracetam plus iron is more effective than iron alone in reducing BHSs in children aged 6 months to 5 years.
屏气发作（BHS）被定义为在诸如愤怒、悲伤和恐惧等初始应激事件、诸如跌倒或头部外伤等疼痛事件或任何应激性心理事件之后发生的呼吸暂停发作。本研究旨在评估左乙拉西坦加铁剂与单独使用铁剂相比，在降低6个月至5岁儿童BHS发作频率方面的疗效。
本研究设计为双盲随机临床试验。将60例6个月至5岁的患者分为两组，第一组（A组）仅接受铁剂治疗，第二组（B组）接受左乙拉西坦加铁剂治疗。在研究结束时，对这些组的治疗效果进行比较分析。
在本研究中，A组治疗前发作的平均次数为3.94±2.69次，治疗后为1.71±1.99次；而B组治疗前发作的平均次数为6.39±5.7次，治疗后为0.37±1.03次。B组治疗后的发作平均次数低于A组。事实上，两组在治疗后的发作次数方面存在显著差异（P = 0.003）。
左乙拉西坦加铁剂在降低6个月至5岁儿童的BHS方面比单独使用铁剂更有效。
